Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.

Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R.

Ann Neurol. 2013 Oct;74(4):622-6. doi: 10.1002/ana.23973. Epub 2013 Sep 16.

PMID:
23868420
2.

Gone over to the dark side: Natalizumab-associated JC virus infection of neurons in cerebellar gray matter.

Dang X, Koralnik IJ.

Ann Neurol. 2013 Oct;74(4):503-5. doi: 10.1002/ana.23985. No abstract available.

3.

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Agnihotri SP, Dang X, Carter JL, Fife TD, Bord E, Batson S, Koralnik IJ.

Neurology. 2014 Aug 19;83(8):727-32. doi: 10.1212/WNL.0000000000000713. Epub 2014 Jul 18.

4.

The human JC polyomavirus (JCPyV): virological background and clinical implications.

Hirsch HH, Kardas P, Kranz D, Leboeuf C.

APMIS. 2013 Aug;121(8):685-727. doi: 10.1111/apm.12128. Epub 2013 Jun 19. Review.

PMID:
23781977
5.

Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.

Jelcic I, Jelcic I, Kempf C, Largey F, Planas R, Schippling S, Budka H, Sospedra M, Martin R.

Ann Neurol. 2016 Mar;79(3):404-18. doi: 10.1002/ana.24574. Epub 2016 Feb 13.

PMID:
26874214
6.

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.

Mult Scler. 2013 Aug;19(9):1226-9. doi: 10.1177/1352458513481010. Epub 2013 Mar 18.

PMID:
23508652
7.

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R.

Brain. 2011 Sep;134(Pt 9):2687-702. doi: 10.1093/brain/awr206.

PMID:
21908874
8.

Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.

Calvi A, De Riz M, Pietroboni AM, Ghezzi L, Maltese V, Arighi A, Fumagalli GG, Jacini F, Donelli C, Comi G, Galimberti D, Scarpini E.

Immunotherapy. 2014;6(1):23-8. doi: 10.2217/imt.13.155.

PMID:
24341880
9.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
10.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
11.

JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy.

Koralnik IJ, Wüthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, Morgello S.

Ann Neurol. 2005 Apr;57(4):576-80.

PMID:
15786466
12.

Update on progressive multifocal leukoencephalopathy.

Steiner I, Berger JR.

Curr Neurol Neurosci Rep. 2012 Dec;12(6):680-6. doi: 10.1007/s11910-012-0313-4. Review.

PMID:
22991070
13.

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.

Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.

Arch Neurol. 2010 Nov;67(11):1391-4. doi: 10.1001/archneurol.2010.157. Epub 2010 Jul 12.

PMID:
20625069
14.

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.

Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.

J Clin Virol. 2013 Jun;57(2):141-6. doi: 10.1016/j.jcv.2013.02.002. Epub 2013 Mar 5.

PMID:
23465394
15.

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML.

Wijburg MT, Siepman D, van Eijk JJ, Killestein J, Wattjes MP.

J Neurol. 2016 Apr;263(4):649-56. doi: 10.1007/s00415-015-8001-3. Epub 2016 Jan 25.

16.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

17.

Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.

Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A; Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group.

N Engl J Med. 2014 Jan 30;370(5):486-8. doi: 10.1056/NEJMc1304828. No abstract available.

18.

The effect of plasma exchange on serum anti-JC virus antibodies.

Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.

Mult Scler. 2013 Jun;19(7):912-9. doi: 10.1177/1352458512467502. Epub 2012 Dec 11.

PMID:
23232602
19.

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, Clifford D, Belachew S.

J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):224-6. doi: 10.1136/jnnp-2011-300511. Epub 2011 Oct 19.

20.

JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration.

Henry C, Jouan F, De Broucker T.

J Neurol Sci. 2015 Jul 15;354(1-2):86-90. doi: 10.1016/j.jns.2015.05.003. Epub 2015 May 9.

PMID:
26003226

Supplemental Content

Support Center